ag凯发k8真人娱乐注册网站

The 13th edition of 黄金城游戏, BIOtech Japan 2014 will take place from May 14 to 16 at Tokyo Big Sight. Consisting of Exhibition, Conference, Partnering and Academic Forum, it gathers 600* exhibitors, 200* presentations and 15,000* visitors. (*expected, including co-held IVD Japan)

Adding new features to the Exhibition and further enriching the Conference program, it becomes more attractive as the focal point of new business, latest trends and innovations.

New features – INDIA as “2014 Partner Country” and new concurrent show on Personalised Medicine
One of the new features this year is “2014 Partner Country” – Republic of India. In addition to the India Pavilion organised by ABLE (Association of Biotechnology Led Enterprises), 2 Indian industry leaders will speak in the Conference. Offering deeper insights to one of the most emerging markets in Asia, BIOtech Japan 2014 further enhances its role as the Asia’s hub of bio business.

The second new feature is the new concurrent show, 1st Personalised Medicine & Diagnostics Expo (IVD Japan 2014). Featuring the growing, Government-led field – Personalised Medicine, it gathers cutting-edge diagnostic/testing 黄金城游戏, 黄金城游戏, contract services, IT, etc. and generates great synergy with BIOtech Japan 2014.

Enriched Conference Program spoken by decision-makers, executives of leading companies, etc.
Also, the Conference program is further enriched, featuring the best speakers of all time. The Keynote Session invites 3 speakers: the decision-makers of Japanese and Indian bio/pharma-related policies and the top management of the major Japanese pharmaceutical company which is showing a robust growth - 1) Mr. Hiroto Izumi, Cabinet Secretariat, Special Advisor to the Prime Minister of Japan, 2) Dr. K. VijayRaghavan, Secretary to the Government of India, Dept. of Biotechnology, Minisitry of Science & Technology and 3) Mr. Yoshihiko Hatanaka, President & CEO of Astellas Pharma.

In addition, executives of leading companies and academic authorities address the hot topics in other sessions, such as Regenerative Medicine (by Dr. Masayuki Yamato of Tokyo Women’s Medical University, co-author of the research paper on STAP cells and Dr. Masayo Takahashi of RIKEN, who was chosen as NATURE’s ‘five to watch’ scientists in 2014), iPS/ES Cells (by Dr. Hideyuki Okano of Keio University School of Medicine, Japan’s highest authority on iPS cells), Antibody Drug (by Mr. Hiroyuki Kawai, Executive Vice President of Kyowa Hakko Kirin Co., Ltd.), "Japanese Version of the NIH" (by Dr. Tomomitsu Hotta, President of National Cancer Center) and many others. Also, more sessions on Personalised Medicine are available at the co-held IVD Japan Conference.

Partnering opportunities with Japanese academics and major pharmaceutical companies
BIOtech Japan 2014 is also a good place for partnering. If you are seeking for partnering opportunities with Japanese researchers with eminent platform technologies/seeds, the Academic Forum will be the best place.

150 academic presenters are expected to present their latest research achievements in various fields such as Pharmaceutical/Diagnostic Drug Seeds, Drug Discovery Tools, Cancer, Medical/Diagnostic Devices, Personalised Medicine, Regenerative Medicine and many others. In addition, you can contact Pharma Company Sponsors consisting of major pharmaceutical companies and request appointments for partnering meetings onsite.

Updated information is available on the website. To receive the latest information and the FREE Invitation Tickets, please register yourself as a visitor on the website www.bio-t.jp/en/.

Contact us
BIOtech Japan Show Management, Reed Exhibitions Japan Ltd.
Attn: Kyoko Nagakusa (Ms.), International PR
TEL: +81-3-3349-8518 / Email: [email protected]
Website: www.bio-t.jp/en/